According to GlobalData’s medical device pipeline database, 21 Artificial Lung devices are in various stages of development globally. GlobalData’s report Artificial Lung provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, seven are in active development, while the remaining 14 are in an inactive stage of development. All devices are in the early stages of development.
Anesthesia and respiratory devices include devices used in administering anesthesia during surgery, devices used in respiratory assistance and respiratory function measurement. An artificial lung (AL) is a device that can temporarily take over the function of the lungs in people with severe respiratory failure. Artificial Lung provides oxygen to the blood and removing carbon dioxide from the blood.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Artificial Lung pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Artificial Lung devices. Overall, most of these Artificial Lung pipeline devices are being developed by private entities.
Key players involved in the active development of Artificial Lung include McGowan Institute for Regenerative Medicine, University of Pittsburgh, Veterans Health Administration, Xenios, Michigan Critical Care Consultants, Miromatrix Medical, Charles Stark Draper Laboratory, U.S. Ann Arbor Healthcare System, University of Michigan and ALung Technologies.
For a complete picture of the developmental pipeline for Artificial Lung devices, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
